ArticleFrontiers in endocrinology2025
Residual cholesterol is independently associated with arteriogenic erectile dysfunction: results from a multi-institutional study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Erectile dysfunction (ED) is increasingly recognized as an early indicator of vascular health, with arteriogenic ED (AED) being the subtype most closely linked to endothelial dysfunction and atherosclerosis. Residual cholesterol (RC), a lipid fraction carried by triglyceride-rich lipoprotein remnants, has emerged as a novel marker of residual cardiovascular and metabolic risk. However, its relationship with ED, particularly AED, has not been well characterized. Methods: From April 2023 to May 2025, men presenting with ED and controls were consecutively recruited from three hospitals. Erectile function was assessed using the International Index of Erectile Function-5 (IIEF-5), nocturnal penile tumescence and rigidity (NPTR), and color duplex Doppler ultrasonography (CDDU) to identify AED. Demographic, lifestyle, clinical, and biochemical data were collected. RC values were calculated using the formula: RC = total cholesterol (TC) - HDL-C - LDL-C. Logistic regression and ROC curve analyses were performed to evaluate the association and predictive value of lipid parameters for AED. Logistic regression analyses were performed to evaluate associations between lipid parameters and ED/AED, adjusting for potential confounders. Results: A total of 216 men with ED and 110 controls were included, among whom 118 were diagnosed with AED. RC levels were significantly higher in the ED group than in controls (0.57 ± 0.33 vs. 0.50 ± 0.18 mmol/L, P = 0.042), although the association with overall ED was attenuated in multivariable analysis (OR 1.086, 95% CI 0.997-1.182, P = 0.058). By contrast, RC remained robustly associated with AED after adjustment for age, BMI, smoking, CVD, TG, and TT (OR 1.471, 95% CI 1.275-1.697, P <0.001). In ROC analysis, RC showed the best predictive performance for AED (AUC 0.726, 95% CI 0.661-0.791), compared with TC (AUC 0.625, 95% CI 0.551-0.699) and TG (AUC 0.581, 95% CI 0.507-0.656). The optimal RC cutoff of 0.595 mmol/L yielded a sensitivity of 61.9% and specificity of 74.5%. Conclusions: RC was independently associated with AED and demonstrated stronger predictive ability than conventional lipid parameters. These findings suggest RC may serve as a useful biomarker for vascular risk stratification in men with ED, although prospective studies are warranted to validate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.